TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06735443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexmetedomidine
Description: children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Tramadol
Description: children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
Study: NCT06734143

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropad
Description: Neuropad examination was performed in all patients, after 10 minutes of rest without socks in a well-temperatured room. The result was considered normal if there was a complete color change and abnormal if there was no or incomplete color change.
Study: NCT06734182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
Description: Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
Study: NCT06736106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening
Description: Comprehensive screening of bone metabolic status and bone fragility in the largest cohort to date of patients with degenerative spinal diseases
Study: NCT06735846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guide wire
Description: Insert the distal end of the guide wire into the introducer sheath and enter the blood vessel through the introducer sheath;5.Insert the catheter directly into the blood vessel through the guide wire, and when the catheter reaches the target position, exit the guide wire.
Study: NCT06735599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry
Description: Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
Study: NCT06735287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bladder sparing set
Description: after neoadjuvant chemotherapy combined with immunotherapy, maximal TURBT and a re-TURBT shall be performed then mitomycin C bladder instillation therapy will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RC
Description: Radical cystectomy performed immediately after three cycles of neoadjuvant therapy.
Study: NCT06734715

Intervention type: OTHER
Intervention: Conservative oxygenation
Description: Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care

Intervention type: OTHER
Intervention: Liberal oxygenation
Description: Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
Study: NCT06734637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b injection
Description: Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
Study: NCT06736054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper 61-PSMA PET/CT
Description: TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
Study: NCT06734676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation (iTBS)
Description: iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Description: iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
Study: NCT06734767

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Stress Reduction 8-week course
Description: The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Stress Reduction 8-week course
Description: The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.
Study: NCT06735586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular control exercise
Description: All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.1st and 2nd (5 times) week exercise program: Non-weight bearing exercises will be given in the first week; lateral hip abduction, clam shell exercises, and bridging exercises. 3rd and 4th week (5 times) exercises: This week investigators will give controlled weight lifting exercises:pelvic drop exercise, single leg squat exercise,step down exercise,single leg raise exercise. 4th and 5 th week exercise: lateral band walks, side lunges, forward lunges, and back lunges. 5 th and 6 th week exercise: Plyometric exercises: jump exercise, BOSU single knee scales exercise,resistive single leg squats,resisting vertical bridge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuromuscular control exercise and taping
Description: Exercises and taping will be done 3 times a week, 10 sets of each exercise. Mulligan Knee Taping Application: The application was made with Protape 38mm x 10 m rigid tape. The application will be performed in the participant's foot, with the hip and knee in internal rotation, and the knee in 20º flexion. The tape will be applied starting from the head of the fibula, passing over the tibia anteriorly, passing under the medial joint line of the knee and ending at the back of the knee, bringing the tibia to internal rotation.
Study: NCT06734650

Intervention type: OTHER
Intervention: peripheral waveform collection
Description: The peripheral venous pressure waveform is collected by connecting a pressure transducer that is currently in use to the placed central venous line. In addition, the pulse pressure variation or stroke volume variation value that can be obtained from the arterial catheter. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithm' study (B-2202-738-401).
Study: NCT06736509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan-bupropion)
Description: AXS-05 tablets, taken twice daily
Study: NCT06736249

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sarcopenic group
Description: The sarcopenic group will undergo a DXA total body to define the sarcopenic stage.

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle harvesting
Description: A piece of discarded muscle during surgery will be collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle harvesting
Description: A piece of discarded muscle during surgery will be collected
Study: NCT05211401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active arm 200 mg
Description: Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active arm 1000 mg
Description: Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
Study: NCT05760846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REAplan®
Description: motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REAplan®
Description: motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum®
Description: motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum®
Description: motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
Study: NCT05682924

Intervention type: DIAGNOSTIC_TEST
Intervention: taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
Description: In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.

Intervention type: DIAGNOSTIC_TEST
Intervention: taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
Description: In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.

Intervention type: DIAGNOSTIC_TEST
Intervention: taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
Description: In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
Study: NCT05505045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Procedures
Description: CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Procedures
Description: Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
Study: NCT05231629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-VRd intensification, Dara-R maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AHCT intensification, Dara-R maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AHCT intensification, Dara-R consolidation, Dara-R maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.

Intervention type: DRUG
Group type: OTHER
Intervention: Dara-VRd induction
Description: Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
Study: NCT06440057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study: NCT06226285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TechQoL4Carers Platform
Description: The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care.
Study: NCT05452811

Intervention type: PROCEDURE
Intervention: Burch colposuspension
Description: Anti-incontinence surgery for stress urinary incontinence

Intervention type: PROCEDURE
Intervention: Burch colposuspension
Description: Anti-incontinence surgery for stress urinary incontinence
Study: NCT04219813

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary test
Description: Detection of the presence of gluten immunogenic peptides (GIP) in the urine of NCGS/NCWS patients, evaluated two times per week, for 5 weeks, and in the event of symptoms/signs that the patients attribute to the accidental intake of gluten, within the same 5 weeks.
Study: NCT06096610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Participants will strength train via linear periodization resistance exercise training.
Study: NCT06244641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auto-questionnaires, hetero-questionnaires and Evoked-potentials
Description: Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
Study: NCT05444335

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable cardiac monitor -Zio patch
Description: Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
Study: NCT05887453

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
Study: NCT06316245

Intervention type: OTHER
Intervention: DASI questionnaire
Description: All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.

Intervention type: OTHER
Intervention: DASI questionnaire
Description: All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.
Study: NCT04788576

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)
Description: In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
Study: NCT05181722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient navigator support
Description: Support of a patient navigator for patients who have experienced an abnormal screening mammogram
Study: NCT05279703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 0.03
Description: epinephrine infusion rate of 0.03 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.02
Description: epinephrine infusion rate of 0.02 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.01
Description: epinephrine infusion rate of 0.01 mcg/kg/min
Study: NCT05999396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of CC-3
Description: Accelerated titration phase, Standard 3+3 titration phase, expansion phase
Study: NCT04603365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT01710683

Intervention type: BEHAVIORAL
Intervention: Care program
Description: Care program with multimodal pain treatment including epidural steroid

Intervention type: BEHAVIORAL
Intervention: Care program
Description: Care program with multimodal pain treatment including epidural steroid.
Study: NCT05085938

Intervention type: PROCEDURE
Intervention: gonadal vein embolization
Description: GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm.